Ascentage Pharma Group InternatAAPG stock score: 45/100
$12.44 · -4.40% · Scored Nov 19, 2026
- Technical
- 22
- Fundamental
- 51
- News
- 51
The reading
Ascentage Pharma Group Internat (AAPG) scores 45 out of 100, which reads weak, higher than 35% of Healthcare stocks and 33% of the 4,118 US stocks we score.
The composite weights fundamentals 80% and technicals 20%: fundamentals read 51, technicals 22.
Among the fundamentals, Price Target at 100 and Revenue Growth (Annual) at 100 score highest, while Earnings Profitability (Quarterly) at 0 weighs the most against it.
On the daily chart, trend-following indicators average 13 and contrarian oscillators 71 — a split worth reading before trusting the technical total.
News sentiment is neutral at 51; it is shown, not counted in the composite.
Since Aug 24, 2026 the composite has ranged from 34 to 48, and it is up 10 points over the period.
About Ascentage Pharma Group Internat
Ascentage Pharma (AAPG) is a biotechnology company based in Suzhou, China, that develops and sells medicines for blood cancers and other cancers. Its first approved drug, olverembatinib, is a third-generation BCR-ABL1 inhibitor approved in China for chronic myeloid leukemia, including drug-resistant disease. Its second, lisaftoclax, is a Bcl-2 inhibitor approved in China for previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma. It is running global registrational trials of both drugs, including lisaftoclax in several blood cancers, and developing other candidates such as APG-5918. Ascentage earns money from sales of its approved drugs in China, which it markets with a commercial partner, and from licensing and collaboration agreements with larger drugmakers, including an option deal with Takeda for olverembatinib outside China. Its shares trade in Hong Kong and, as American depositary shares, on Nasdaq.
Ascentage competes with larger companies that sell treatments for leukemia and lymphoma, including Novartis, AbbVie and BeOne Medicines. Its edge rests on in-house research in protein-protein interactions and apoptosis, a pair of drugs already approved in China and data from patients who failed earlier therapies. Investors who follow AAPG stock tend to watch results from its global registrational trials and regulatory filings outside China. Sales of olverembatinib and lisaftoclax are closely followed. Partnership milestones, cash runway, operating expenses and trade relations between the United States and China are other factors.
What’s driving the score
The strongest and weakest of the scorers that count toward AAPG’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.
Fundamental
51Pulling it up
- Price Target100
Price target score compares the current stock price to analyst consensus targets.
Annual revenue growth tracks year-over-year sales expansion.
How the latest quarter's revenue compares with the average of the last four, plus a bonus for steady quarterly revenue.
Holding it back
Earnings Profitability (Quarterly) measures recent profitability using trailing 12-month quarterly data.
Net income growth against the same quarter a year earlier, weighted toward the latest quarter.
Absolute profitability: whether the company is profitable, its net margin against the sector range, and how consistently it has been profitable over three years.
37 weighted scorers; 2 had no data today and are left out rather than counted as zero.
Technical · daily
19Pulling it up
Bollinger Bands (20-period) plot standard deviations above and below a moving average.
Bollinger Bands (50-period) measure where price sits between bands two standard deviations around its 50-period average.
Williams %R (28-period) places the close within the last 28 periods' high-low range.
Holding it back
S&P 500 52-week comparison evaluates the stock's annual performance relative to the broader market.
Candlestick patterns recognize specific price formations that historically suggest continuation or reversal.
The price change over the last 52 weeks.
62 weighted scorers; 3 had no data today and are left out rather than counted as zero.
News · shown, not counted
- Global News
- 51
Technical score by timeframe
| Chart | Score | Weight |
|---|---|---|
| Hourly | 33 | 1 |
| Daily | 19 | 3 |
| Weekly | 22 | 2 |
Composite score, last 90 days
Show the daily numbers
| Date | Composite |
|---|---|
| Nov 20, 2026 | 45 |
| Nov 19, 2026 | 46 |
| Nov 18, 2026 | 45 |
| Nov 16, 2026 | 48 |
| Nov 14, 2026 | 47 |
| Nov 13, 2026 | 48 |
| Nov 11, 2026 | 39 |
| Nov 8, 2026 | 39 |
| Nov 7, 2026 | 39 |
| Nov 6, 2026 | 38 |
| Nov 5, 2026 | 38 |
| Nov 4, 2026 | 36 |
| Nov 3, 2026 | 36 |
| Nov 2, 2026 | 36 |
| Oct 31, 2026 | 37 |
| Oct 30, 2026 | 38 |
| Oct 29, 2026 | 37 |
| Oct 28, 2026 | 38 |
| Oct 27, 2026 | 40 |
| Oct 26, 2026 | 39 |
| Oct 25, 2026 | 39 |
| Oct 24, 2026 | 39 |
| Oct 23, 2026 | 37 |
| Oct 22, 2026 | 41 |
| Oct 21, 2026 | 40 |
| Oct 20, 2026 | 39 |
| Oct 19, 2026 | 38 |
| Oct 18, 2026 | 39 |
| Oct 17, 2026 | 39 |
| Oct 16, 2026 | 36 |
| Oct 15, 2026 | 37 |
| Oct 14, 2026 | 38 |
| Oct 13, 2026 | 37 |
| Oct 12, 2026 | 37 |
| Oct 11, 2026 | 37 |
| Oct 10, 2026 | 37 |
| Oct 9, 2026 | 37 |
| Oct 8, 2026 | 37 |
| Oct 7, 2026 | 39 |
| Oct 6, 2026 | 36 |
| Oct 5, 2026 | 36 |
| Oct 4, 2026 | 37 |
| Oct 3, 2026 | 36 |
| Oct 2, 2026 | 38 |
| Oct 1, 2026 | 39 |
| Sep 30, 2026 | 37 |
| Sep 29, 2026 | 36 |
| Sep 28, 2026 | 35 |
| Sep 27, 2026 | 36 |
| Sep 26, 2026 | 36 |
| Sep 25, 2026 | 38 |
| Sep 24, 2026 | 38 |
| Sep 23, 2026 | 38 |
| Sep 22, 2026 | 37 |
| Sep 21, 2026 | 36 |
| Sep 20, 2026 | 36 |
| Sep 19, 2026 | 36 |
| Sep 18, 2026 | 36 |
| Sep 17, 2026 | 34 |
| Sep 16, 2026 | 35 |
| Sep 15, 2026 | 35 |
| Sep 14, 2026 | 35 |
| Sep 13, 2026 | 35 |
| Sep 12, 2026 | 35 |
| Sep 11, 2026 | 36 |
| Sep 10, 2026 | 37 |
| Sep 9, 2026 | 38 |
| Sep 8, 2026 | 38 |
| Sep 7, 2026 | 37 |
| Sep 6, 2026 | 38 |
| Sep 5, 2026 | 38 |
| Sep 4, 2026 | 37 |
| Sep 3, 2026 | 36 |
| Sep 2, 2026 | 37 |
| Sep 1, 2026 | 36 |
| Aug 31, 2026 | 38 |
| Aug 30, 2026 | 39 |
| Aug 29, 2026 | 38 |
| Aug 28, 2026 | 41 |
| Aug 27, 2026 | 35 |
| Aug 26, 2026 | 36 |
| Aug 25, 2026 | 36 |
| Aug 24, 2026 | 35 |
Key facts
- Market cap
- $1.2B
- Sector
- Healthcare
- Industry
- Biotechnology
- Beta
- 0.77
- Risk grade (1–10)
- —
- Next earnings
- —
Biotechnology peers
| Company | Market cap | Score |
|---|---|---|
| TSHA Taysha Gene Therapies | $1.2B | 47 |
| GPCR Structure Therapeutics | $1.2B | 29 |
| SVRA Savara | $1.1B | 38 |
| VOR Vor Biopharma | $1.1B | 43 |
| NKTR Nektar Therapeutics | $1.1B | 27 |
| INBX Inhibrx Biosciences | $1.1B | 38 |
Questions
What is AAPG's stock rating today?
AAPG scores 45/100 (Weak) as of Nov 19, 2026: technical 22, fundamental 51, and news sentiment 51, which is shown but not counted. Scores are recomputed every night.
What does Ascentage Pharma Group Internat do?
Ascentage Pharma (AAPG) is a biotechnology company based in Suzhou, China, that develops and sells medicines for blood cancers and other cancers. Its first approved drug, olverembatinib, is a third-generation BCR-ABL1 inhibitor approved in China for chronic myeloid leukemia, including drug-resistant disease.
Is AAPG stock a buy?
The score is not a buy or sell recommendation. A 45 says the technical and fundamental signals we measure lean weak today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.
How is the AAPG score calculated?
99 weighted scorers feed it today: 37 fundamental, scored against Healthcare ranges, and 62 technical on the daily chart, with 3 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.
Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.
Embed this score
A badge for a blog post, newsletter or README. It updates every night and links back here. More badges
HTML
<a href="https://stocksscores.com/stocks/aapg/"><img src="https://stocksscores.com/stocks/aapg/badge.svg" alt="AAPG stock score" height="20"></a>
Markdown
[](https://stocksscores.com/stocks/aapg/)